<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478529</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-033</org_study_id>
    <nct_id>NCT01478529</nct_id>
  </id_info>
  <brief_title>A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation</brief_title>
  <official_title>A Single Dose, Open Label, Randomized, Two-period Cross Over Study in Healthy Male Subjects to Assess the Absolute Bioavailability of YM178 OCAS-M Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate how much of the active compound of mirabegron comes into the blood
      circulation when given as a controlled-release pill as compared to given intravenously.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants will receive both oral and iv formulations, separated by a washout period.
      Treatment arm A will receive a lower dose of mirabegron; Treatment arm B will receive a
      higher dose of mirabegron.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of pharmacokinetics of mirabegron assessed by plasma concentration</measure>
    <time_frame>Pre-dose until 72 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitoring of safety and tolerability through assessment of vital signs, Electrocardiogram (ECG), clinical safety laboratory and adverse events</measure>
    <time_frame>Baseline until 72 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pharmacokinetics of Mirabegron</condition>
  <condition>Bioavailability</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose of mirabegron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose of mirabegron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirabegron OCAS</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <other_name>YM178 OCAS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirabegron</intervention_name>
    <description>iv administration</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <other_name>YM178</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight between 60.0 and 100.0 kg and Body Mass Index between 18.0 and 30.0 kg/m2

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to β-adrenergic receptor agonists or constituents
             of the formulations used

          -  Clinically significant elevation of serum creatinine or liver enzymes as evidenced by
             creatinine &gt;150 ųmol/L; ASAT, ALAT or LDH&gt; 2x ULN; ɣ-GT &gt; 3x ULN and/or abnormal serum
             bilirubin

          -  Any clinically significant history of asthma, eczema, any other allergic condition or
             previous severe hypersensitivity to any drug

          -  Subjects taking β blockers or β agonists (eye drops allowed)

          -  Any clinically significant history of upper gastrointestinal symptoms (such as nausea,
             vomiting, abdominal discomfort or upset, or heartburn) in the 4 weeks prior to the
             first admission to the Research Unit

          -  Any clinically significant history of any other disease or disorder -
             gastrointestinal, cardiovascular, respiratory, ophthalmologic, renal, hepatic,
             neurological, dermatological, psychiatric or metabolic

          -  Any clinically significant abnormality following the investigator's review of the
             pre-study physical examination, ECG and clinical laboratory tests

          -  QTcB interval of &gt; 430 (mean QTcB of two measurements &gt; 430msec)

          -  Abnormal pulse rate measurement (&lt;40 or &gt;90 bpm) at the pre-study visit after subject
             has been resting in supine position for 5 min.

          -  Abnormal blood pressure measurements taken at the pre-study visit after subject has
             been resting in supine position for 5 min as follows:

               -  Systolic blood pressure &lt;95 or &gt;160 mmHg

               -  Diastolic blood pressure &lt;40 or &gt;90 mmHg

          -  Positive orthostatic test at screening i.e. any symptoms of dizziness,
             light-headedness etc. and a fall of &gt; 20 mmHg in systolic blood pressure after 2 min
             standing and an increase in pulse rate of ≥ 20 bpm

          -  Regular use of any prescribed or OTC drugs except paracetamol up to 3 g/day, in the 4
             weeks prior to admission to the Research Unit OR any use of such drugs in the 2 weeks
             prior to first admission to the Research Unit
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharma Bio Research</name>
      <address>
        <city>Zuidlaren</city>
        <zip>9470 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=680</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <reference>
    <citation>Eltink C, Lee J, Schaddelee M, Zhang W, Kerbusch V, Meijer J, van Marle S, Grunenberg N, Kowalski D, Drogendijk T, Moy S, Iitsuka H, van Gelderen M, Matsushima H, Sawamoto T. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther. 2012 Nov;50(11):838-50. doi: 10.5414/CP201782.</citation>
    <PMID>22943933</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2011</study_first_submitted>
  <study_first_submitted_qc>November 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>Phase 1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

